Anti-neoangiogenic nanodelivery systems: advances in tumor-based and ophthalmic disease research
(Note: The full text of this document is currently only available in the PDF Version )
Bingjie Guo , Zhaokai Li , Junyi Zhou , Ruobei Shu , Wuhao Wei , Yanting Kuang , Youfa Xu and Xin Wu
First published on 19th September 2025
Abstract
Abnormal neovascularization plays a critical role in the progression of various diseases, with tumor and ophthalmic neovascularization sharing many core mechanisms. As a result, anti-angiogenic drugs have become one of the key therapeutic strategies for such diseases. However, these drugs face significant limitations, such as toxic side effects, limited bioavailability, and the tendency to develop drug resistance. In recent years, with a deeper understanding of angiogenic mechanisms, nanodrug delivery systems have demonstrated significant advantages in anti-angiogenic therapy, particularly in terms of precise delivery, sustained drug release, and tissue targeting. This review summarizes recent advances in the application of anti-angiogenic nanodrug delivery systems in the treatment of tumors and ophthalmic diseases, including their mechanisms of action. It focuses on delivery strategies of nanocarriers and highlights research progress in functionalized and combination therapy-based nanodrug delivery systems for anti-angiogenesis. Finally, the opportunities and challenges of such systems are discussed.